Hematopoietic colony-stimulating factors (CSF) decrease the duration of neutropenia following stem cell transplantation (SCT). With CSF-mobilized allogeneic blood SCT (alloBSCT), the yields of CD34
of neutropenia. [1] [2] [3] [4] [5] [6] As a result, there is uncertainty about whether colony-stimulating factors (CSFs) can provide additional benefit following allogeneic blood stem cell transplantation (alloBSCT).
There is some evidence from the SCT literature that posttransplant CSF use leads to both clinical and economic benefits. Randomized studies have found a 4 to 5 day decrease in the duration of neutropenia with G-CSF or GM-CSF following autologous SCT and following allogeneic bone marrow SCT. [7] [8] [9] [10] [11] [12] Two studies reported economic benefits with adjunctive G-CSF use following autologous SCT. 8, 13 McQuaker et al 8 found that lymphoma patients who received G-CSF following autologous bone marrow transplantation had a shortened inpatient stay and required less intravenous antibiotics. Klumpp et al 13 found that breast cancer patients who received G-CSF following autologous blood stem cell transplantation incurred lower total costs, primarily due to savings associated with shortening of the period required for post-transplant antibiotics.
We recently reported a 4.5 day benefit in neutropenia duration with post-transplant G-CSF following allogeneic peripheral blood stem cell transplant patients.
14 This randomized clinical trial provides an opportunity to evaluate whether the additional costs of 10 or more days of posttransplant CSF use can be offset by potential cost savings associated with the 4.5 day improvement in the duration of neutropenia. Here, we report on resource use and cost profiles for the G-CSF and the placebo arm in the clinical trial, using methodology developed in prior economic analyses of clinical studies of CSF use in the stem cell transplantation setting.
Patients and methods

Clinical protocol
The findings from the clinical trial have been reported previously.
14 Briefly, adult patients (age 16-65) with hematologic malignancies (acute myelogeneous leukemia (AML), chronic myelogenous leukemia (CML), non-Hodgkin's lymphoma (NHL), myelodysplastic syndrome (MDS), chronic lymphocytic (CLL) and multiple myeloma (MM)) and a five to six HLA antigen-matched family donor were enrolled on the study at two sites, University of Nebraska Medical Center (n = 44) and St. Luke's Hospital-Kansas
Bone Marrow Transplantation City (n = 10). A minimum of 3 × 10 6 CD34 + cells/kg and 6.5 × 10 8 mononuclear cells/kg were collected from donors following mobilization with G-CSF (10 g/kg/day). The preparative regimen consisted of inpatient treatment with cyclophosphamide (60 mg/kg/day × 2 days) and hyperfractionated total body irradiation (200 cGy twice a day ×3 days). Patients were randomized to receive G-CSF (10 g/kg/day) or placebo via subcutaneous injection daily post transplant until neutrophil recovery (absolute neutrophil count (ANC) у1000 cells/l for 3 consecutive days) beginning on day 0. Graft-versus-host disease (GVHD) prophylaxis consisted of intravenous cyclosporin A given every 12 h starting on day −3 followed by oral cylosporine when tolerated, and methotrexate (5 mg/m 2 ) i.v. given on days +1, +3, +6, +11.
6 Broad-spectrum intravenous antibiotics were given for fevers Ͼ38°C or ANC Ͻ500 cells/l. No routine antifungal prophylaxis was given. Intravenous antibiotic prophylaxis was administered when the ANC dipped below 0.5 × 10 9 /l and continued until neutrophil recovery. Platelet transfusions were administered for platelet counts Ͻ20 000 l or if bleeding occurred. Packed red blood cells were transfused to maintain a hemoglobin level over 8 g/dl, or if symptomatic. All patients were discharged at the discretion of the treating physician, but generally the decision was based on the following criteria: absence of fever or infections, able to take oral medications, minimum oral intake of 1000 cc fluid and 1000 kcal, controlled GVHD, absence of infection, ambulatory, and need for no more than one blood or platelet transfusion per day. After hospital discharge, patients received additional care and follow-up (including twice a week complete blood counts, chemistries, and physician visits, weekly chest radiographs, and bone marrow evaluations at day +28 and day +100) unless rehospitalization was necessary.
Cost analysis
A cost minimization study was conducted from the thirdparty payer perspective for the 44 patients treated at the University of Nebraska Medical Center. The patients included in this economic analysis made up 80% of the cohort of patients included in the phase III randomized study. Clinical characteristics and outcomes of this subset of patients did not differ significantly from the results reported for the entire cohort (Table 1) . We used both a methodology and a financial data base system that have been evaluated in prior economic analyses from this institution over the past decade. [15] [16] [17] [18] Detailed financial accounts for each patient were obtained from the University of Nebraska Medical Center financial data bases, containing units, charges and costs for each line item. Inpatient and outpatient costs from all departments (excluding physician fees) from day 0 to day +100 were included.
Median values for resource units, total costs, and costs by department were compared for each treatment arm. Costs of administration of placebo were excluded from the cost summary. The median cost of hospital stay was $1015 per day. Median intravenous antibiotic costs, including cost of administration, were $87 per day for ceftazidime, $79 per day for cefepime and $131 per day for acyclovir and the cost of G-CSF was estimated at $200 per day. Values were 
Results
Clinical characteristics and outcomes for the 44 study patients are described in Table 1 . The median age of the G-CSF and placebo group was approximately 42 years, with a majority of patients being male. A variety of hematologic malignancies was treated in this study, with the majority of patients having NHL or CML. The median number of CD34 + cells transplanted was 10.4 × 10 6 /kg for G-CSF patients and 8.1 × 10 6 /kg for placebo patients (P = 0.43). Patients who received adjunctive G-CSF had a significantly shorter time period to ANC у500 cells/l (median of 10.5 vs 15 days, P Ͻ 0.001). Median days to platelet recovery (13 days for G-CSF patients vs 14 days for placebo patients), incidence of acute GVHD (52% vs 60%), and 100 day survival (74% vs 86%) did not statistically differ between groups. These findings are similar to those reported for the entire cohort of 54 patients. 14 Median resource use and costs for both study arms are reported in Tables 2 and 3 . Post-transplant resources were used at a similar intensity for the G-CSF and placebo patients. Patients were hospitalized for a median of 21 days in the G-CSF arm and 22 days in the placebo arm, received a median of 6.5 days of total parenteral nutrition (TPN) vs 5.5 days, and received intravenous antibiotics for a median of 16 days vs 18 days (P = NS). Both G-CSF and placebo patients received a median of 4 units of red blood cells and 7 units of platelets. Outpatient post-transplant follow-up visits were a median of 33 for the placebo patients and 29 for the G-CSF patients. Median total post-transplant inpatient costs for the G-CSF vs placebo patients were $64 369 vs $64 789, inclusive of the G-CSF costs (P = 0.52). The two study groups did not differ significantly with respect to inpatient costs of hospital room, pharmacy, blood products, laboratory, respiratory care, radiology or supplies costs. Overall, total median inpatient plus outpatient costs of care were similar, $76 577 for the G-CSF patients vs $78 799 for the placebo patients, inclusive of the costs of post-transplant CSF use (P = 0.93).
Discussion
We evaluated the economic outcomes for patients enrolled in a phase III randomized study of G-CSF use post alloBSCT. The clinical results from this phase III study of
Bone Marrow Transplantation post-transplant G-CSF use are similar in magnitude to those reported previously for autologous SCT patients. 7-9,13 A median of 4.5 days savings in the duration of neutropenia for alloBSCT patients is about the same as that reported for G-CSF use following autologous blood SCT for breast or lymphoma patients. 7, 8 In contrast, while two studies of autoBSCT patients found savings in the duration of hospitalization and overall medical costs with post-transplant G-CSF use, 8, 13 in this study, the intensity of post-transplant resources, duration of hospitalization, and overall costs were not lower when G-CSF was used post alloBSCT.
This study is the fifth report of cost findings for SCT patients from the University of Nebraska Medical Center, one of the centers with extensive experience of SCTs for persons with hematologic malignancies and one of the first centers to report on costs of SCTs. [15] [16] [17] [18] Previously, we reported that costs of alloBSCT were $18 000 lower than for alloBMT among persons with hematologic malignancies, primarily due to shortening of the duration of neutropenia and lowered post-transplant costs. 15 We also found empirical support suggesting that a clinical and economic 'learning curve' exists for SCT patients. [15] [16] [17] [18] From 1987 to 1995, the development of new supportive care technologies, a shift to blood stem cell support, the use of coordinated outpatient facilities, organizational modifications, and the cost-effective use of diagnostic procedures and pharmaceuticals resulted in improvements in inpatient mortality for non-Hodgkin's lymphoma patients undergoing autologous SCT from 40% to 3% and a greater than 65% savings in costs. 16, 17 The fourth study found evidence of economic benefits during the early investigational period of G-CSF and GM-CSF support for SCT patients at high experience SCT centers, but not at SCT centers with lower levels of experience. 18 The limitations of our study must be noted. First, the sample size of this study is small, while costs were variable. As a consequence, comparisons of median costs rather than mean costs were reported. However, our findings were qualitatively similar if mean costs were compared. Moreover, the sample size, 44 patients, is similar to that included in prior economic analyses of phase III randomized controlled trials of CSFs for hematologic malignancies. [19] [20] [21] Second, the estimates of costs of care and resource utilization were derived for alloBSCT patients treated on a clinical trial at a large academic transplant center and are likely to differ from those in settings with smaller caseloads and less experience with SCT. 18 Third, the use of peripheral blood stem cells for alloSCT is still undergoing clinical investigation, with early studies showing short-term clinical and economic benefits, but raising concerns over potentially higher rates of chronic GVHD. 22, 23 It is unknown if the initiation of growth factor on the same day as stem cell transplant is optimal, biologically or economically. Future studies will need to evaluate long-term clinical and economic outcomes for large cohorts of alloSCT patients. Finally, the absence of explicit criteria for hospital discharge may have affected the duration of hospitalization for some patients in this study. Despite significant shortening of the median duration of post-transplant neutropenia with G-CSF, delays in hospital discharge may have resulted from the absence of these criteria in the study protocol.
Similar findings of improvements in duration of neutropenia without concomitant benefits in duration of hospitalization, were noted in early studies of CSFs for autoBMT prior to the inclusion of discharge criteria in the study protocol. 18 In summary, post-transplant G-CSF use for patients who undergo alloBSCT resulted in a 4.5 day improvement in the median day of neutrophil recovery and did not incur additional costs, but did not result in shortening of the duration of hospitalization or decreased intravenous antibiotic use. Physicians should consider post-alloBSCT G-CSF use based on clinical, rather than economic, considerations.
